Claritev Corp
Close on Oct 19, 2026
- Market cap
- $372.55M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 6, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 7, 2026 | Before market open | $257.50M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | $244.70M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 23, 2026 | After market close | $246.60M | $-4.88 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 7, 2025 | Before market open | $246.00M | $-4.23 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 25, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 5, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 29, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 7, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Capital expenditures | Updated FY 2026 Guidance\n(as of 8/7/2026) | $160.00M to $170.00M | Maintained |
| Adjusted EBITDAnon-GAAP | Updated FY 2026 Guidance\n(as of 8/7/2026) | $610.00M to $620.00M | Raised |
| Free Cash Flownon-GAAP | Updated FY 2026 Guidance\n(as of 8/7/2026) | $5.00M to $15.00M | Raised |
| Effective tax rate | Updated FY 2026 Guidance\n(as of 8/7/2026) | 24% to 28% | Maintained |
| Revenues | Updated FY 2026 Guidance\n(as of 8/7/2026) | $1.00B to $1.02B | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Claritev filed with the SEC
Claritev Appoints Jennifer Main to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Claritev Appoints Ben Letham to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Claritev Corporation Reports Second Quarter 2026 Results
Results of operations · EX-99.1 to Form 8-K
Claritev Corporation Reports First Quarter 2026 Results
Results of operations · EX-99.1 to Form 8-K
Confidential and Proprietary – Do not distribute without permission 1 New York Stock Exchange March 16, 2026 2026 Investor Day
Regulation FD disclosure · EX-99.1 to Form 8-K
Claritev Corporation Reports Fourth Quarter and Full Year 2025 Results
Results of operations · EX-99.1 to Form 8-K
4 01 Claritev Vision 02 Products and Offerings Agenda 03 Financial Overview
Regulation FD disclosure · EX-99.1 to Form 8-K
Claritev Corporation Reports Third Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
3 01 Claritev Vision 02 Product and Offerings 03 Technology 04 Financial Overview Agenda 05 Strategic Growth Initiatives
Regulation FD disclosure · EX-99.1 to Form 8-K
Claritev Corporation Reports Second Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
Claritev Corporation Reports First Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
Claritev Reports Fourth Quarter and Full Year 2024 Results with Initial Guidance for Full Year 2025
Results of operations · EX-99.1 to Form 8-K
MultiPlan Enters New Era and Unveils New Brand, Claritev, Reflecting Company’s Transformation and Mission to Support the Healthcare Continuum
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
MultiPlan Announces Expiration and Results of
Other events · EX-99.1 to Form 8-K
extended for entire debt capital structure, with earliest funded maturity in 2030 and remainder
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MultiPlan Announces Commencement of Exchange Offers
Material agreement · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
MultiPlan Reports Third Quarter 2024 Results and Updates 2024 Guidance
Results of operations · EX-99.1 to Form 8-K
MultiPlan Corporation’s Reverse Stock Split Becomes Effective
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
MultiPlan Corporation Announces Effective Date of Reverse Stock Split
Shareholder vote results · Other events · EX-99.1 to Form 8-K
Jim Head, who has served as EVP and CFO of MultiPlan since November 2021, will transition to a strategic advisor to the Company through the end of the year to ensure a smooth transition .
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
MultiPlan Reports Second Quarter 2024 Results and Updates 2024 Guidance
Results of operations · EX-99.1 to Form 8-K
MultiPlan Reports First Quarter 2024 Results
Results of operations · EX-99.1 to Form 8-K
MultiPlan Corporation Receives Continued Listing Standard Notice from NYSE
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
MultiPlan Appoints Jerry Hogge as Chief Operating Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
MultiPlan Reports Fourth Quarter and Full Year 2023 Results
Results of operations · EX-99.1 to Form 8-K
Growth Strategy and Next Phase of Product Innovation
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
MultiPlan Reports Third Quarter 2023 Results
Results of operations · EX-99.1 to Form 8-K
MultiPlan Reports Second Quarter 2023 Results
Results of operations · EX-99.1 to Form 8-K
MultiPlan Acquires Leading Healthcare Data and Analytics Firm Benefits Science LLC
Material agreement · Acquisition or disposition completed · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Years Ended December 31, 2022 and 2021
Material agreement · Acquisition or disposition completed · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS
Material agreement · Acquisition or disposition completed · Unregistered share sale · Regulation FD disclosure · EX-99.3 to Form 8-K
MultiPlan Reports First Quarter 2023 Results
Results of operations · EX-99.1 to Form 8-K